← Back to Clinical Trials
Recruiting NCT05205980

NCT05205980 Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05205980
Status Recruiting
Phase
Sponsor Georgia State University
Condition Alzheimer Disease
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2023-04-28
Primary Completion 2026-10-30

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Perturbation training

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2023-04-28 with a primary completion date of 2026-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.

Eligibility Criteria

Inclusion Criteria: * Participants must be at least 65 years old; * Participants have a clinical diagnosis of probable AD; * Participants can read and understand English; * Participants must be able to walk independently at least 25 feet; * Participants must be able to stand independently for at least 30 seconds; * Participants must have a Montreal Cognitive Assessment score of 11-21 or Mini Mental Status Examination score between 18 and 23. Exclusion Criteria: * Individuals have ever experienced perturbation training; * Individuals have hypotension or uncontrolled hypertension; * Individuals exhibit osteoporosis; * Participants suffer from coexisting psychiatric disorders, or other neurological conditions, or injuries, etc.

Contact & Investigator

Central Contact

Feng Yang, PhD

✉ fyang@gsu.edu

📞 404-413-8357

Principal Investigator

Feng Yang, PhD

PRINCIPAL INVESTIGATOR

Georgia State University

Frequently Asked Questions

Who can join the NCT05205980 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, up to 90 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05205980 currently recruiting?

Yes, NCT05205980 is actively recruiting participants. Contact the research team at fyang@gsu.edu for enrollment information.

Where is the NCT05205980 trial being conducted?

This trial is being conducted at Valdosta, United States.

Who is sponsoring the NCT05205980 clinical trial?

NCT05205980 is sponsored by Georgia State University. The principal investigator is Feng Yang, PhD at Georgia State University. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology